Japan approved its 39-trillion-yen economic stimulus package on November 22. It does not explicitly state that the drug price revision…
HOME > ARCHIVE
ARCHIVE
- Nesina Approved for Combination with Actos: Takeda
September 6, 2010
- Fatal Familial Insomnia Seen by the Smallest Number of Doctors: SSRI, M3 Survey
September 6, 2010
- Generics Use Rate Up 0.9 Points to 18.9% on Volume Basis in FY2009
September 6, 2010
- Takepron Approved for Prevention of NSAID-Associated Ulcers
September 6, 2010
- Carna Biosciences Embarks on Contract Drug Discovery Business
September 6, 2010
- Merck Serono to Enter CNS Field by Launching Cladribine by 2014
September 6, 2010
- ImmuCyst Approved for Adjuvant Therapy after TURBT
September 6, 2010
- Tella Ties Up with Jikei University for Vaccine Therapy
September 6, 2010
- Sanofi-aventis to Take Over Genzyme
September 6, 2010
- Revlimid Approved for Myelodysplastic Syndrome
September 6, 2010
- JPMA's Biopharmaceutical Committee Gears Up Activities
September 6, 2010
- Novartis Licenses Rabies Vaccine to Kaketsuken
September 6, 2010
- Precedex Approved for Long-Term Administration of over 24 Hours
September 6, 2010
- Takara Bio Begins Clinical Research for TCR Gene Therapy
September 6, 2010
- Genzyme Licenses Synvisc to Teijin Pharma
September 6, 2010
- Denosumab Applied for Bone Metastases: Daiichi Sankyo
September 6, 2010
- Towa to Expand Production Capacity with New Plant
September 6, 2010
- JCMOA to Be Kicked Off in October
September 6, 2010
- Banyu Files an NDA for Daptomycin
September 6, 2010
- Perampanel Shows Efficacy for Refractory Partial Seizure in PIII: Eisai
September 6, 2010
ページ
For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…